Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen as diagnostic and therapeutic tools for prostate cancer
Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
1. An antigen binding portion of an isolated monoclonal antibody which
a) binds to prostate specific membrane antigen in its native form occurring on the surface of tumor cells
b) binds strongly to LNCAP cells but not or only minimally to cells which lack expression of prostate specific membrane antigen,
c) comprises at least three sequences selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16, and
d) is part of a diabody which binds to T-cell receptor complex.
2. The antigen binding portion according to claim 1 which shows a high binding activity to LNCAP cells reaching 50% saturation of PSMA sites at concentrations between 1 nM and 120 nM.
3. The antigen binding portion according to claim 1 , characterized in that said diabody is bispecific for PSMA and the CD3 chain of a T-cell receptor complex.
4. The antigen binding portion according to claim 3 , characterized in that said diabody has the ability to induce tumor cell lysis by redirecting T-cells, which results in T-cell mediated cytotoxicity.
5. A pharmaceutical composition comprising an antigen binding portion according to claim 1 .
6. A method of treating cancer comprising administering the pharmaceutical composition according to claim 5 to a subject in need thereof.